Evidence map›Paper›PMID 34719673›Full record

ArticleBone research2021

An antibody against Siglec-15 promotes bone formation and fracture healing by increasing TRAP

Gehua Zhen, Yang Dan, Ruomei Wang, Ce Dou, Qiaoyue Guo, Melissa Zarr, Linda N Liu, Lieping Chen, Ruoxian Deng, Yusheng Li and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Loss ofGenes · 2024
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Gehua Zhen *Department of Orthopedic Surgery, Institute of Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-7652-6226
Yang Dan *Department of Orthopedic Surgery, Institute of Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ruomei WangDepartment of Orthopedic Surgery, Institute of Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ce DouDepartment of Orthopedic Surgery, Institute of Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Qiaoyue GuoDepartment of Orthopedic Surgery, Institute of Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Melissa ZarrNextCure, Inc., Beltsville, MD, USA.
Linda N LiuNextCure, Inc., Beltsville, MD, USA.
Lieping ChenDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
Ruoxian DengDepartment of Orthopedic Surgery, Institute of Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yusheng LiDepartment of Orthopedic Surgery, Institute of Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Zengwu ShaoDepartment of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xu CaoDepartment of Orthopedic Surgery, Institute of Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA. xcao11@jhmi.edu.
Johns Hopkins University · USUnion Hospital · CNYale University · US

Funding

Skeleton and Joint Degeneration with AgingP01AG066603 · NIA · JOHNS HOPKINS UNIVERSITY · PI CAO, XU · 2021 to 2025
$9.2M
NIA NIH HHS P01 AG066603
6 · The paper itself

Abstract

Osteoporosis (OP) is a common age-related disease characterized by a deterioration of bone mass and structure that predisposes patients to fragility fractures. Pharmaceutical therapies that promote anabolic bone formation in OP patients and OP-induced fracture are needed. We investigated whether a neutralizing antibody against Siglec-15 can simultaneously inhibit bone resorption and stimulate bone formation. We found that the multinucleation of osteoclasts was inhibited in SIGLEC-15 conditional knockout mice and mice undergoing Siglec-15 neutralizing antibody treatment. The secretion of platelet-derived growth factor-BB (PDGF-BB), the number of tartrate-resistant acid phosphatase-positive (TRAP

Identifiers

PMID34719673
PMCPMC8558327
OpenAlexW3209354358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.